Literature DB >> 32363394

Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.

Swikriti Dasgupta1, Michio Imamura2,3, Evan Gorstein1, Takashi Nakahara2,3, Masataka Tsuge2,3, Alexander Churkin4, David Yardeni5, Ohad Etzion5, Susan L Uprichard1, Danny Barash6, Scott J Cotler1, Harel Dahari1, Kazuaki Chayama3,4.   

Abstract

We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  direct-acting antivirals; hepatitis C virus; mathematical modeling; response-guided therapy

Mesh：

Substances：

Year:  2020        PMID： 32363394      PMCID： PMC7768761          DOI： 10.1093/infdis/jiaa219

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  12 in total

1.  Utility of viral kinetics in HCV therapy - It is not over until it is over?

Authors:  Lisa Sandmann; Michael P Manns; Benjamin Maasoumy
Journal:  Liver Int       Date:  2019-05       Impact factor: 5.828

2.  Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Authors:  Kazuki Ohya; Michio Imamura; Mitsutaka Osawa; Yuji Teraoka; Kei Morio; Hatsue Fujino; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Akira Hiramatsu; Masataka Tsuge; Hiroshi Aikata; Clair Nelson Hayes; Kazuaki Chayama
Journal:  Clin J Gastroenterol       Date:  2019-08-28

3.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

4.  EASL Recommendations on Treatment of Hepatitis C 2018.

Authors: 
Journal:  J Hepatol       Date:  2018-04-09       Impact factor: 25.083

5.  Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Authors:  Martina Gambato; Laetitia Canini; Sabela Lens; Frederik Graw; Elena Perpiñan; Maria-Carlota Londoño; Susan L Uprichard; Zoe Mariño; Enric Reverter; Concepcio Bartres; Patricia González; Anna Pla; Josep Costa; Patrizia Burra; Scott J Cotler; Xavier Forns; Harel Dahari
Journal:  Liver Int       Date:  2018-12-28       Impact factor: 5.828

6.  Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.

Authors:  George Lau; Yves Benhamou; Guofeng Chen; Jin Li; Qing Shao; Dong Ji; Fan Li; Bing Li; Jialiang Liu; Jinlin Hou; Jian Sun; Cheng Wang; Jing Chen; Vanessa Wu; April Wong; Chris L P Wong; Stella T Y Tsang; Yudong Wang; Leda Bassit; Sijia Tao; Yong Jiang; Hui-Mien Hsiao; Ruian Ke; Alan S Perelson; Raymond F Schinazi
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-07-25

7.  FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

Authors:  Anaïs Vallet-Pichard; Vincent Mallet; Bertrand Nalpas; Virginie Verkarre; Antoine Nalpas; Valérie Dhalluin-Venier; Hélène Fontaine; Stanislas Pol
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

8.  Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.

Authors:  Mark Nelson; Gail V Matthews; Marianne Martinello; Chloe Orkin; Graham Cooke; Sanjay Bhagani; Edward Gane; Ranjababu Kulasegaram; David Shaw; Elise Tu; Kathy Petoumenos; Philippa Marks; Jason Grebely; Gregory J Dore
Journal:  Hepatology       Date:  2020-04-08       Impact factor: 17.425

9.  Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.

Authors:  Robert S Brown; Maria Buti; Lino Rodrigues; Vladimir Chulanov; Wan-Long Chuang; Humberto Aguilar; Gábor Horváth; Elimelech Zuckerman; Barbara Rosado Carrion; Federico Rodriguez-Perez; Petr Urbánek; Armand Abergel; Eric Cohen; Sandra S Lovell; Gretja Schnell; Chih-Wei Lin; Jiuhong Zha; Stanley Wang; Roger Trinh; Federico J Mensa; Margaret Burroughs; Franco Felizarta
Journal:  J Hepatol       Date:  2019-11-02       Impact factor: 25.083

10.  HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Authors:  Laetitia Canini; Michio Imamura; Yoshiiku Kawakami; Susan L Uprichard; Scott J Cotler; Harel Dahari; Kazuaki Chayama
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240
View more
  6 in total

1.  Modeling based response guided therapy in subjects with recent hepatitis C infection.

Authors:  Evan Gorstein; Marianne Martinello; Alexander Churkin; Swikriti Dasgupta; Kevin Walsh; Tanya L Applegate; David Yardeni; Ohad Etzion; Susan L Uprichard; Danny Barash; Scott J Cotler; Gail V Matthews; Harel Dahari
Journal:  Antiviral Res       Date:  2020-06-25       Impact factor: 5.970

2.  Machine learning for mathematical models of HCV kinetics during antiviral therapy.

Authors:  Alexander Churkin; Stephanie Kriss; Asher Uziel; Ashish Goyal; Rami Zakh; Scott J Cotler; Ohad Etzion; Amir Shlomai; Horacio G Rotstein; Harel Dahari; Danny Barash
Journal:  Math Biosci       Date:  2021-12-06       Impact factor: 2.144

3.  Utility of On-Treatment Viral Loads During Treatment With Direct-Acting Antivirals in Patients Infected With Chronic Viral Hepatitis C.

Authors:  Shila Mortazavi; Lauren M Hynicka
Journal:  J Pharm Technol       Date:  2022-06-04

4.  Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.

Authors:  Vladimir Reinharz; Alexander Churkin; Harel Dahari; Danny Barash
Journal:  Mathematics (Basel)       Date:  2022-06-19

5.  Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.

Authors:  Ashish Goyal; Alex Churkin; Danny Barash; Scott J Cotler; Amir Shlomai; Ohad Etzion; Harel Dahari
Journal:  Open Forum Infect Dis       Date:  2022-03-22       Impact factor: 4.423

6.  Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.

Authors:  Ohad Etzion; Harel Dahari; David Yardeni; Assaf Issachar; Anat Nevo-Shor; Michal Cohen-Naftaly; Yaffa Ashur; Susan L Uprichard; Orly Sneh Arbib; Daniela Munteanu; Marius Braun; Scott J Cotler; Naim Abufreha; Ayelet Keren-Naus; Yonat Shemer-Avni; Orna Mor; Jayanah Murad; Victor Novack; Amir Shlomai
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.